New hope for patients with pulmonary hypertension: endothelin receptor antagonists: update for the clinical nurse specialist.

P. O'Malley

DOI: https://doi.org/10.1097/00002800-200409000-00005

2004-09-01

Abstract:Primary pulmonary hypertension is a rare but deadly disease with an annual incidence of 1 to 2 cases per million people. The incidence is higher (25–50 persons per million) for persons using appetite suppressants. Mean survival time is 2.8 years after diagnosis if untreated and with limited treatment options, overall prognosis and quality of life is poor. On average, there is up to a 3-year delay between the onset of symptoms and the diagnosis. The incidence of secondary pulmonary hypertension is unknown and is associated with chronic lung conditions, thrombo-embolic disease, mitral valve disease, left to right shunts, systemic sclerosis, collagen vascular disease, and human immunodeficiency virus. The prevalence rate for pulmonary hypertension varies from 2.3% to 35% for those with scleroderma. Pulmonary vasoconstriction, vascular remodeling, and thrombosis result in breathlessness, chest pain, and syncope with progression to right-sided heart failure. Traditional treatment options include prostacyclin, nitric oxide, calcium channel blockers, phosphodiesterase inhibitors, and adjunctive therapies of anticoagulants and supplemental oxygen. Intravenous prostacyclin and inhaled nitric oxide can increase exercise capacity but require permanent venous access and a continuous inhalation delivery system. While calcium channel blockers are often considered as the first option for therapy, they are effective in 30% or less of patients. Anticoagulants and calcium channel blockers improve the poor prognosis, but they generally do not improve the quality of life. The efficacy of phosphodiesterase inhibitors has not yet been confirmed.